A report from Lux Research says nanotechnology may hold promise in developing and delivering drugs, but the major pharmaceutical companies are not investing in the research to find out. Although the NIH and its National Cancer Institute are exploring the new technology, the drugmaking firms are not, according to the report, which warns this may allow the competition to jump ahead, much as the biotech industry did 20 years ago.

Full Story:

Related Summaries